Bank of America
ALDX icon

Bank of America’s Aldeyra Therapeutics ALDX Stock Holding History

Bank of America’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$364K Sell
215,332
-194,696
-47% -$853K ﹤0.01% 5058
2025
Q4 		$2.12M Buy
410,028
+19,950
+5% +$102K ﹤0.01% 4018
2025
Q3 		$2.04M Buy
390,078
+333,587
+591% +$1.74M ﹤0.01% 4807
2025
Q2 		$216K Sell
56,491
-352,051
-86% -$910K ﹤0.01% 6146
2025
Q1 		$2.35M Buy
408,542
+102,296
+33% +$605K ﹤0.01% 4541
2024
Q4 		$1.53M Sell
306,246
-69,147
-18% -$355K ﹤0.01% 4674
2024
Q3 		$2.02M Sell
375,393
-3,097
-0.8% -$14.7K ﹤0.01% 4554
2024
Q2 		$1.25M Sell
378,490
-20,461
-5% -$80.1K ﹤0.01% 4758
2024
Q1 		$1.3M Buy
398,951
+25,031
+7% +$82.3K ﹤0.01% 4759
2023
Q4 		$1.31M Buy
373,920
+76,495
+26% +$236K ﹤0.01% 4778
2023
Q3 		$1.99M Buy
297,425
+748
+0.3% +$5.55K ﹤0.01% 4247
2023
Q2 		$2.49M Buy
296,677
+137,221
+86% +$1.35M ﹤0.01% 4030
2023
Q1 		$1.58M Buy
159,456
+71,965
+82% +$509K ﹤0.01% 4551
2022
Q4 		$609K Sell
87,491
-19,015
-18% -$109K ﹤0.01% 5229
2022
Q3 		$568K Sell
106,506
-26,103
-20% -$157K ﹤0.01% 5306
2022
Q2 		$529K Buy
132,609
+41,316
+45% +$142K ﹤0.01% 5403
2022
Q1 		$406K Sell
91,293
-243,596
-73% -$970K ﹤0.01% 5979
2021
Q4 		$1.34M Buy
334,889
+241,835
+260% +$1.84M ﹤0.01% 4962
2021
Q3 		$818K Sell
93,054
-5,211
-5% -$47.8K ﹤0.01% 5250
2021
Q2 		$1.11M Buy
98,265
+63,943
+186% +$769K ﹤0.01% 4814
2021
Q1 		$408K Buy
34,322
+26,853
+360% +$309K ﹤0.01% 5526
2020
Q4 		$51K Buy
+7,469
New +$52.4K ﹤0.01% 6321
2020
Q3 		– Sell
-11,659
Closed -$49K – 6861
2020
Q2 		$49K Buy
11,659
+1,070
+10% +$3.91K ﹤0.01% 5990
2020
Q1 		$26K Sell
10,589
-1,424
-12% -$6.41K ﹤0.01% 6087
2019
Q4 		$70K Sell
12,013
-1,920
-14% -$11.1K ﹤0.01% 6136
2019
Q3 		$74K Buy
13,933
+2,745
+25% +$14.8K ﹤0.01% 6182
2019
Q2 		$68K Buy
11,188
+5,229
+88% +$39.4K ﹤0.01% 6174
2019
Q1 		$54K Sell
5,959
-6,222
-51% -$52.9K ﹤0.01% 6163
2018
Q4 		$102K Buy
12,181
+7,093
+139% +$72.7K ﹤0.01% 5901
2018
Q3 		$70K Buy
5,088
+1,990
+64% +$16.1K ﹤0.01% 6044
2018
Q2 		$24K Sell
3,098
-1,517
-33% -$12.1K ﹤0.01% 6444
2018
Q1 		$35K Buy
4,615
+1,115
+32% +$8.46K ﹤0.01% 6179
2017
Q4 		$24K Sell
3,500
-4,000
-53% -$26.3K ﹤0.01% 6356
2017
Q3 		$54K Sell
7,500
-1,500
-17% -$7.83K ﹤0.01% 5907
2017
Q2 		$42K Buy
9,000
+1,000
+13% +$4.6K ﹤0.01% 5938
2017
Q1 		$40K Buy
8,000
+2,000
+33% +$10.3K ﹤0.01% 6023
2016
Q4 		$32K Buy
6,000
+2,000
+50% +$11.7K ﹤0.01% 6116
2016
Q3 		$31K Buy
4,000
+746
+23% +$4.56K ﹤0.01% 5931
2016
Q2 		$18K Buy
3,254
+1,254
+63% +$7K ﹤0.01% 6286
2016
Q1 		$8K Buy
+2,000
New +$9.61K ﹤0.01% 6440

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of America's ALDX Position: Q1 2026 in Review

Bank of America reduced its Aldeyra Therapeutics (ALDX) stake by 47% in Q1 2026, selling an estimated $853K and leaving 215,332 shares worth $364K. The position accounts for ﹤0.01% of the portfolio, ranked #5058.

Bank of America first reported a position in ALDX in Q1 2016 and has held it in 40 quarters since. The position peaked at $2.49M in Q2 2023. 127 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Bank of America held 215,332 shares of Aldeyra Therapeutics worth $364K as of Q1 2026.
  • Bank of America sold 194,696 Aldeyra Therapeutics shares in Q1 2026, an estimated $853K.
  • Aldeyra Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5058 holding.
  • Bank of America first reported a position in Aldeyra Therapeutics in Q1 2016 and has held it in 40 quarters since.
  • Bank of America's Aldeyra Therapeutics position peaked at $2.49M in Q2 2023.
  • 127 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.